

CaD, calcium dobesilate;

MoA, mechanism of action. ALL 1. Liu J, et al. Calcium dobesilate and micro-vascular diseases. *Life Sci* 2019;221:348–353. 2. Angulo J, et al. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate. *Eur J Pharmacol* 2011;667(1–3):153–159. 3. Zhou Y, et al. Diabetic nephropathy can be treated with calcium dobesilate by alleviating the chronic inflammatory state and improving endothelial cell function. *Cell Physiol Biochem* 2018;51(3):1119–1133. 4. Doxium® CCDS version 5.0. 2023. 5. Doxiproct® CCDS version 3.0. 2023. 6. Doxiproct Plus® CCDS version 3.0. 2023

7. De Maeseneer MG et al., European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. *Eur J Vasc Endovasc Surg*. 2022 Feb;63(2):184-267.